



Universiteit
Leiden
The Netherlands

Structural and functional abnormalities of left-sided cardiac chambers in Barlow's disease without significant mitral regurgitation

Meucci, M.C.; Mantegazza, V.; Wu, H.W.; Wijngaarden, A.L. van; Garlaschè, A.; Tamborini, G.; ... ; Marsan, N.A.

Citation

Meucci, M. C., Mantegazza, V., Wu, H. W., Wijngaarden, A. L. van, Garlaschè, A., Tamborini, G., ... Marsan, N. A. (2024). Structural and functional abnormalities of left-sided cardiac chambers in Barlow's disease without significant mitral regurgitation. *European Heart Journal - Cardiovascular Imaging*, 25(9), 1396-1305. doi:10.1093/ehjci/jeae121

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4198070>

Note: To cite this publication please use the final published version (if applicable).

Structural and functional abnormalities of left-sided cardiac chambers in Barlow's disease without significant mitral regurgitation

Maria Chiara Meucci ^{1,2}, Valentina Mantegazza^{3,4}, Hoi W. Wu¹,
Aniek L. van Wijngaarden¹, Anna Garlaschè³, Gloria Tamborini³, Mauro Pepi ³,
Jeroen J. Bax^{1,5}, and Nina Ajmone Marsan ^{1*}

¹Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands; ²Department of Cardiovascular Science, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; ³Department of Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy; ⁴Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy; and ⁵Heart Center, University of Turku, Turku University Hospital, Turku, Finland

Received 5 November 2023; revised 8 April 2024; accepted 13 April 2024; online publish-ahead-of-print 6 May 2024

Aims

This study aims to explore the presence of left ventricular (LV) and left atrial (LA) morphological and functional abnormalities in patients with Barlow's disease (BD) without significant mitral regurgitation (MR) and to investigate whether these abnormalities may predict MR progression.

Methods and results

Consecutive patients with BD were retrospectively identified from two tertiary centres; those with MR graded from trivial to mild-to-moderate were selected and matched with healthy controls in a 1:1 ratio. Conventional and speckle-tracking echocardiographic data were collected. The development of moderate-to-severe or greater MR was evaluated on follow-up echocardiograms. Patients with BD ($n = 231$) showed increased LV dimensions and indexed LV mass (LVMI) in comparison with controls ($P < 0.001$); LV remodelling worsened with higher MR severity and was accompanied by an increased prevalence of eccentric LV hypertrophy (eLVH). Moreover, BD patients had larger LA volumes and more impaired LA reservoir strain vs. controls ($P < 0.001$), while LV strain was similar between the two groups. Multivariable linear regression analyses in the overall population identified BD and MR grade as independent predictors of remodelling markers (LV dimensions, LVMI, and LA volume) and BD as independent correlate of LA strain. MR progression was observed in 51 BD subjects (out of 170 patients with available follow-up). On Cox regression analysis, age, eLVH, mild-to-moderate MR, and mitral annular disjunction (MAD) emerged as independent predictors of MR progression.

Conclusion

BD patients without significant MR show early LV and LA remodelling, together with reduced LA strain. MR progression was associated with eccentric LV remodelling, MAD, and MR severity.

* Corresponding author. E-mail: n.ajmone@lumc.nl

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Table 1 Clinical and echocardiographic features of the study population

	BD (n = 231)	Controls (n = 231)	P-value
Clinical variables			
Age (years)	48 ± 15	47 ± 12	0.602
Female gender (n, %)	130 (55)	119 (52)	0.305
Hypertension (n, %)	27 (12)	28 (12)	0.645
Hypercholesterolemia (n, %)	19 (8)	22 (10)	0.822
Diabetes (n, %)	1 (0.5)	6 (3)	0.124
Obesity (n, %)	1 (0.5)	4 (2)	0.372
PAF (n, %)	16 (7)	10 (4)	0.313
CAD (n, %)	3 (1)	3 (1)	0.922
COPD (n, %)	2 (1)	4 (2)	0.469
Creatinine (mg/dL)	0.87 ± 0.19	0.88 ± 0.20	0.816
NYHA functional class			0.999
I/II/III-IV (n)	210/20/0	210/20/0	
Syncope (n, %)	9 (4)	3 (1)	0.141
Echocardiographic variables			
LVEDDi (mm/m ²)	28.1 ± 3.6	25.4 ± 2.9	<0.001
LVESDi (mm/m ²)	16.7 ± 3.3	15.6 ± 2.6	<0.001
IVS thickness (mm)	9 (8–10)	10 (8–11)	0.053
PW thickness (mm)	9 (8–11)	9 (8–10)	0.329
LVMi (g/m ²)	93 (80–109)	81 (72–93)	<0.001
eLVH (n, %)	66 (29)	17 (7)	<0.001
LVEDVi (mL/m ²)	61 ± 12	51 ± 9	<0.001
LVESVi (mL/m ²)	24 ± 6	20 ± 5	<0.001
LVEF (%)	61 ± 6	61 ± 5	0.314
LVGLS (%)	20.5 ± 2.7	20.2 ± 2.4	0.165
LAVi max (mL/m ²)	35 ± 12	25 ± 8	<0.001
LAVi min (mL/m ²)	17 ± 9	11 ± 5	<0.001
LA sphericity index	0.84 ± 0.11	0.78 ± 0.09	<0.001
LA reservoir strain (%)	31.2 ± 8.0	34.4 ± 7.0	<0.001
E/A ratio	1.2 (0.9–1.5)	1.3 (0.9–1.6)	0.365
E/e' ratio	7.0 (6.0–8.4)	6.8 (5.7–8.0)	0.082
MV annulus (mm)	34 ± 5	28 ± 3	<0.001
MAD (n, %)	91 (39)	-	-
Mild-to-moderate MR	102 (44)	0 (0)	<0.001
TAPSE (mm)	25 ± 4	24 ± 3	0.002
TV annulus (mm)	32 (30–36)	31 (27–35)	0.001
TR grade (n, %)			0.015
Trivial or mild	224 (97)	231 (100)	
Mild-to-moderate	7 (3)	0 (0)	
TR jet velocity (m/s)	2.2 (2.0–2.4)	2.3 (2.1–2.4)	0.111
PASP (mmHg)	25 (22–29)	26 (22–29)	0.101

BD, Barlow's disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; IVS, interventricular septum; LA, left atrial; LAVi, indexed LA volume; LV, left ventricular; eLVH, eccentric LV hypertrophy; LVEDDi, indexed LV end-diastolic diameter; LVESDi, indexed LV end-systolic diameter; LVEDVi, indexed LV end-diastolic volume; LVESVi, indexed LV end-systolic volume; LVEF, LV ejection fraction; LVGLS, LV global longitudinal strain; LVMi, indexed LV mass; MAD, mitral annular disjunction; MV, mitral valve; NYHA, New York Heart Association; PAF, paroxysmal atrial fibrillation; PASP, pulmonary arterial systolic pressure; TR, tricuspid regurgitation; TV, tricuspid valve.

expressed as a dichotomous variable, eLVH was also independently associated with MR progression, after adjustment for age, MR grade, presence of MAD, and LAVi max (hazard ratio 2.251; 95% confidence

interval 1.195–4.240, $P = 0.012$). Event-free survival rates in BD population stratified according to MR grade or the presence of MAD or eLVH are shown in Figure 4A–C, respectively.




Figure 2 Parameters of left-sided chamber remodelling stratified according to MR severity in BD patients: LVMI, LVEDVi, LAVi max and LA reservoir strain (A–D). Asterisks indicate statistically significance ($P < 0.05$). BD, Barlow's disease; LA, left atrial; LAVi max, indexed maximal LA volume; LV, left ventricular; LVEDVi, indexed LV end-diastolic volume; LVMI, indexed LV mass; ns, non-significant.

Discussion

The main findings of the present study can be summarized as follows: (i) Patients with BD and MR grade from trivial to mild-to-moderate show early LV and LA remodelling, together with a mild impairment of LA reservoir strain, but not of LV systolic function as compared with matched controls; (ii) these abnormalities of BD are at least partially independent from MR severity (within a range of non-significant MR grade); (iii) MR progression during follow-up was associated with baseline MR grade and also with the presence of eccentric LV remodelling and MAD.

Early abnormalities of left-sided chambers in BD patients without significant MR

In asymptomatic patients with severe primary MR, current indications for MV intervention rely on the assessment of the haemodynamic impact of MR and thus primarily on parameters of LV dimensions and function (i.e. with LV end-systolic diameter > 40 mm or LVEF $< 60\%$ providing a class I recommendation for surgery). On the other hand, initial studies have suggested that in patients with MVP, especially with BD phenotype, LV enlargement and systolic impairment may be disproportionate in relation to MR severity,^{5–7} challenging the assumption that LV remodelling is a direct effect of the MR-related volume overload.

However, the concept of disproportionate LV remodelling in MVP patients has been criticized by other authors^{8,18} and to date remains controversial. Particularly, the theory of a 'prolapse volume', which would determine LV volume overload on top of the transvalvular MR volume, has been postulated by El-Tallawi *et al.*,⁸ while an alternative hypothesis to explain these findings relies on the methodological variability of LV volumes quantification.¹⁸ Moreover, whether the presence of early remodelling of left-sided chambers in BD may have clinical and prognostic implications is currently unknown.

In the echocardiographic study performed by Yang *et al.*,⁷ 253 MVP patients with less than moderate MR exhibited larger LV and LA dimensions and higher LVMI than matched controls; however, an advanced analysis of myocardial mechanics to better address the myocardial damage was not provided. Our results confirm and further expand the findings reported by Yang *et al.*, in a multi-centric, selected cohort of BD patients. In the present study, patients with BD and MR graded from trivial to mild-to-moderate showed early LV and LA enlargement, together with an increased prevalence of eLVH and impaired LA mechanics in comparison with matched subjects, while conventional and speckle-tracking parameters of LV systolic performance were similar between the two groups. Notably, despite LV and LA remodelling worsen in parallel to MR severity, current findings were confirmed when only the subset of BD patients with trivial or mild MR was included in the comparative analysis. In addition, multivariable linear regression

Table 2 Multivariable linear regression analyses for LVMI, LVEDVi, LAVi max, and LA strain in the overall population

	Unstandardized B (95% CI)	SE (B)	Standardized beta	P-value
1) Multivariable regression for LVMI				
Age	0.212 (0.077–0.347)	0.069	0.140	0.002
Male gender	9.765 (6.164–13.366)	1.832	0.233	<0.001
Hypertension	4.274 (–1.300 to 9.848)	2.836	0.068	0.133
BD	8.813 (4.305–13.320)	2.293	0.210	<0.001
Mild-to-moderate MR	11.483 (6.292–16.673)	2.614	0.227	<0.001
MAD	–2.985 (–8.270 to 2.301)	2.689	–0.055	0.268
2) Multivariable regression for LVEDVi				
Age	–0.169 (–2.41 to –0.096)	0.037	–0.193	<0.001
Male gender	6.617 (4.685–8.549)	0.983	0.272	<0.001
BD	6.128 (3.710–8.546)	1.230	0.253	<0.001
Mild-to-moderate MR	6.714 (3.929–9.499)	1.417	0.229	<0.001
MAD	3.710 (0.874–6.545)	1.443	0.118	0.010
3) Multivariable regression for LAVi max				
Age	0.158 (0.089–0.226)	0.035	0.193	<0.001
PAF	4.698 (0.777–8.618)	1.995	0.095	0.019
E/e' ratio	0.376 (–0.097 to 0.848)	0.240	0.069	0.119
BD	7.370 (5.300–9.440)	1.053	0.323	<0.001
Mild-to-moderate MR	5.998 (3.397–8.599)	1.324	0.214	0.010
4) Multivariable regression for LA reservoir strain				
Age	–0.124 (6.557–23.173)	0.028	–0.224	<0.001
Male gender	–2.206 (–0.178 to –0.069)	0.666	–0.146	0.001
PAF	–1.087 (–3.821 to 1.647)	1.391	–0.034	0.435
Hypertension	0.162 (–1.805 to 2.129)	0.999	0.007	0.872
LVGLS	0.860 (0.611–1.110)	0.127	0.294	<0.001
LA sphericity index	13.514 (7.412–19.616)	3.104	0.194	<0.001
E/e' ratio	–0.444 (–0.799 to –0.110)	0.170	–0.124	0.009
BD	–4.353 (–5.900 to –2.805)	0.787	–0.288	<0.001
Mild-to-moderate MR	1.400 (–0.479 to 3.279)	0.956	0.076	0.144

BD, Barlow's disease; CI, confidence interval; LA, left atrial; LAVi, indexed LA volume; LVEDVi, indexed LV end-diastolic volume; LVGLS, LV global longitudinal strain; LVMI, indexed LV mass; MAD, mitral annular disjunction; MR, mitral regurgitation; PAF, paroxysmal atrial fibrillation.

baseline MR grade were not clearly reported. In the study from Yang *et al.*,⁸ among 153 patients with MVP and follow-up echocardiographic data, an isolated involvement of the posterior leaflet was associated with a higher risk of developing moderate-to-severe or greater MR, while parameters of LV remodelling or MAD were not. Conversely, in the present cohort, eccentric LV remodelling emerged as independent predictors of MR progression, together with older age, MR severity, and MAD. These discordant findings may be primarily related to the different characteristics of the two cohorts, since the study by Yang *et al.* was conducted in a mixed MVP population, including either patients with BD and FED, as confirmed by a considerably older mean age (61 vs. 48 years), and adopting a lower threshold of MR severity (EROA < 20 mm² and Rvol < 30 mL), as inclusion criteria.

The association between higher LVMI and MR worsening may have important clinical implications, since patients with eccentric LV remodelling may benefit from a tailored follow-up strategy, with closer echocardiographic surveillance and screening of other potential aetiologies, including ventricular arrhythmias. Despite chronologically causality may not be ascertained from our study, it is conceivable that eLVH may reflect a more severe disease phenotype, which is also associated with an

increased risk of MR progression. Similarly, the presence of MAD may act a predisposing factor for the evolution of MV abnormalities and MR severity, as a consequence of the abnormal annular mechanics and increased mechanical stress on the MV apparatus.¹⁴

Whether BD patients with less than severe MR and LV remodelling may benefit from an earlier referral for MV intervention may not be ascertained from our study and deserve future specifically designed investigations.


Limitations

Several limitations of the current study should be mentioned. First, this study concerns a retrospective analysis of patients referred to two high-volume tertiary centres and selection bias cannot be fully excluded. Therefore, future prospective studies are warranted to confirm our findings. Accurate grading of MR severity in patients with BD may be challenging, especially in patients with multiple and eccentric jets, with the risk of underestimating MR severity. In our study, the echocardiographic analysis of MR severity was optimized as performed by experts and confirmed after discussion with a second observer and

Table 3 Univariable and multivariable Cox regressions for MR progression in BD patients

	Univariable		Multivariable (1)		Multivariable (2)	
	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P
Age (years)	1.041 (1.019–1.062)	<0.001	1.041 (1.018–1.065)	<0.001	1.041 (1.017–1.066)	<0.001
Male gender	1.464 (0.822–2.606)	0.195	-	-	-	-
Hypertension	1.589 (0.816–3.093)	0.173	-	-	-	-
PAF	1.277 (0.536–2.809)	0.628	-	-	-	-
LVMi (g/m ²)	1.022 (1.010–1.034)	<0.001	1.015 (1.002–1.028)	0.020	1.017 (1.004–1.031)	0.012
LVEDVi (mm/m ²)	1.021 (0.997–1.045)	0.088	-	-	-	-
LVESVi (mm/m ²)	1.007 (0.961–1.055)	0.764	-	-	-	-
LVEF (%)	1.025 (0.979–1.073)	0.294	-	-	-	-
LVGLS (%)	1.014 (0.916–1.123)	0.784	-	-	-	-
LAVi max (mL/m ²)	1.030 (1.009–1.051)	0.004	-	-	0.998 (0.974–1.022)	0.849
LAVi min (mL/m ²)	1.025 (0.997–1.053)	0.077	-	-	-	-
LA strain (%)	0.994 (0.956–1.033)	0.750	-	-	-	-
E/e' ratio	1.125 (1.007–1.258)	0.038	1.021 (0.888–1.173)	0.772	-	-
Bileaflet MVP	0.978 (0.472–2.028)	0.953	-	-	-	-
MAD	1.891 (1.085–3.298)	0.025	1.912 (1.059–3.452)	0.031	1.865 (1.051–3.308)	0.033
Mild-to-moderate MR	2.664 (1–509–4.704)	0.001	2.312 (1.226–4.359)	0.007	2.060 (1.108–3.827)	0.022

Abbreviations: as in Figures 1 and 2.



adopting a multi-parametric approach. Nevertheless, quantitative parameters of MR severity obtained by CMR imaging would have provided additive diagnostic value. History of paroxysmal AF was not an exclusion criterion for the present study, but its prevalence in our BD cohort was very low (3%) and the statistical analyses were adjusted for this factor. Finally, cardiopulmonary testing was not performed in most of the patients and, thereby, correlating study findings with exercise capacity was not feasible.

Conclusion

BD patients without significant MR display early LV and LA remodelling, together with mild impairment of LA reservoir strain, but not of LV function. The presence of eccentric LV remodelling, together with MAD and a higher MR grade, portend an increased risk of MR

progression and patients with these features may benefit from a closer follow-up strategy.

Supplementary data

Supplementary data are available at *European Heart Journal - Cardiovascular Imaging* online.

Funding

None declared.

Conflict of interest: The Department of Cardiology, Heart Lung Center, Leiden University Medical Center, received research grants from Abbott Vascular, Alnylam, Bayer, BioVentrix, Biotronik, Boston Scientific, Edwards Lifesciences, GE Healthcare, Medtronic, Medis, Novartis, Pfizer,

and Pie Medical. J.J.B. received speaker fees from Abbott Vascular. N.A.M. received speaker fees from Abbott Vascular, GE Healthcare, Philips Ultrasound, and Omnor.

Data availability

The data that support the results of this study are available from the corresponding author upon reasonable request.

References

1. Pye LL, Bertrand PB, Paelinck BP, Heidbuchel H, Van Craenenbroeck EM, Van De Heyning CM. Left ventricular remodeling in non-syndromic mitral valve prolapse: volume overload or concomitant cardiomyopathy? *Front Cardiovasc Med* 2022;**9**:862044.
2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J* 2022;**43**: 561–632.
3. Hiemstra YL, Tomsic A, van Wijngaarden SE, Palmen M, Klautz RJM, Bax JJ et al. Prognostic value of global longitudinal strain and etiology after surgery for primary mitral regurgitation. *JACC Cardiovasc Imaging* 2020;**13**:577–85.
4. Stassen J, van Wijngaarden AL, Butcher SC, Palmen M, Herbots L, Bax JJ et al. Prognostic value of left atrial reservoir function in patients with severe primary mitral regurgitation undergoing mitral valve repair. *Eur Heart J Cardiovasc Imaging* 2022;**24**:142–51.
5. Yiginer O, Kaser N, Ozmen N, Tokatli A, Kardesoglu E, Isilak Z et al. Classic mitral valve prolapse causes enlargement in left ventricle even in the absence of significant mitral regurgitation. *Echocardiography* 2012;**29**:123–9.
6. Malev E, Reeva S, Vasina L, Timofeev E, Pshepiy A, Korshunova A et al. Cardiomyopathy in young adults with classic mitral valve prolapse. *Cardiol Young* 2014;**24**:694–701.
7. Yang LT, Ahn SW, Li Z, Benfari G, Mankad R, Takeuchi M et al. Mitral valve prolapse patients with less than moderate mitral regurgitation exhibit early cardiac chamber remodeling. *J Am Soc Echocardiogr* 2020;**33**:815–25. e2.
8. El-Tallawi KC, Kitkungvan D, Xu J, Cristini V, Yang EY, Quinones MA et al. Resolving the disproportionate left ventricular enlargement in mitral valve prolapse due to Barlow disease: insights from cardiovascular magnetic resonance. *JACC Cardiovasc Imaging* 2021;**14**:573–84.
9. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. *Eur Heart J* 2010;**31**:1958–66.
10. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European association of cardiovascular imaging. *Eur Heart J Cardiovasc Imaging* 2013;**14**:611–44.
11. Lang RM, Badano LP, Mor-Avi V, Afzal J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015;**16**:233–70.
12. Meucci MC, Fortuni F, Galloo X, Bootsma M, Crea F, Bax JJ et al. Left atrioventricular coupling index in hypertrophic cardiomyopathy and risk of new-onset atrial fibrillation. *Int J Cardiol* 2022;**363**:87–93.
13. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2016;**17**:1321–60.
14. Hiemstra YL, Tomsic A, Gripari P, van Wijngaarden AL, van der Pas SL, Palmen M et al. Evolution from mitral annular dysfunction to severe mitral regurgitation in Barlow's disease. *Interact Cardiovasc Thorac Surg* 2021;**32**:506–14.
15. Badano LP, Kolias TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/industry task force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging* 2018;**19**:591–600.
16. Asch FM, Miyoshi T, Addetia K, Citro R, Daimon M, Desale S et al. Similarities and differences in left ventricular size and function among races and nationalities: results of the world alliance societies of echocardiography normal values study. *J Am Soc Echocardiogr* 2019;**32**:1396–406. e2.
17. Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state-of-the-art review. *J Am Coll Cardiol* 2019;**73**:1961–77.
18. Wolff R, Uretsky S. Defining the left ventricular base in mitral valve prolapse: impact on systolic function and regurgitation. *Int J Cardiovasc Imaging* 2020;**36**:2221–7.
19. Ajmone Marsan N, Graziani F, Meucci MC, Wu HW, Lillo R, Bax JJ et al. Valvular heart disease and cardiomyopathy: reappraisal of their interplay. *Nat Rev Cardiol* 2024;**21**: 37–50.
20. Roselli C, Yu M, Nauffal V, Georges A, Yang Q, Love K et al. Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. *Eur Heart J* 2022;**43**:1668–80.
21. van Wijngaarden AL, Hiemstra YL, Koopmann TT, Ruivenkamp CAL, Aten E, Schaliij MJ et al. Identification of known and unknown genes associated with mitral valve prolapse using an exome slice methodology. *J Med Genet* 2020;**57**:843–50.
22. Constant D, Beaufils AL, Huttin O, Jobbe-Duval A, Senage T, Filippetti L, Piriou N et al. Replacement myocardial fibrosis in patients with mitral valve prolapse: relation to mitral regurgitation, ventricular remodeling, and arrhythmia. *Circulation* 2021;**143**:1763–74.
23. Tremblay-Gravel M, Ichimura K, Picard K, Kawano Y, Dries AM, Haddad F et al. Intrinsic atrial myopathy precedes left ventricular dysfunction and predicts atrial fibrillation in Lamin A/C cardiomyopathy. *Circ Genom Precis Med* 2023;**16**:e003480.
24. Lee AP, Jin CN, Fan Y, Wong RHL, Underwood MJ, Wan S. Functional implication of mitral annular disjunction in mitral valve prolapse: a quantitative dynamic 3D echocardiographic study. *JACC Cardiovasc Imaging* 2017;**10**:1424–33.
25. Delling FN, Rong J, Larson MG, Lehman B, Fuller D, Osypuk E et al. Evolution of mitral valve prolapse: insights from the Framingham heart study. *Circulation* 2016;**133**: 1688–95.